BYD-AUTO
21.11.2023 02:00:47 CET | Business Wire | Press release
BYD, the world’s leading manufacturer of new energy vehicles, showcased its full lineup of vehicles at the 21st Guangzhou International Automobile Exhibition from November 17th to 26th. BYD featured the global debut of the e⁴ concept car, the release of the Supercar Platform, and the unveiling of the new pure electric SUV—the BYD Sea Lion 07 EV*.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120172380/en/
New concept car of Yangwang (Photo: Business Wire)
Yangwang Unveiled a New e⁴ Concept Car and Supercar Platform
BYD's premium sub-brand Yangwang dazzled with the debut of its latest e⁴ concept car, supercar platform, and brought U8 and U9 to the auto show. The e⁴ concept car by Yangwang lacked traditional steering gear and braking mechanisms. It employed a three-in-one technology for driving, braking, and steering, eliminating the need for conventional mechanical systems. Earlier this year, Yangwang introduced the exclusive Yangwang Architecture for high-end new energy vehicles. The Supercar Platform under this architecture made its official debut, marking Yangwang's transition from the wilderness to the racetrack with cutting-edge technology. At the exhibition, the interior of the Yangwang U9 was unveiled for the first time, showcasing a cockpit that exuded both technological sophistication and sportiness.
Sea Lion 07 EV*: A New Member of the BYD Ocean Series
BYD Ocean Series unveiled its first mid-sized pure electric SUV, the Sea Lion 07 EV*, at the exhibition. Embracing the 'Ocean Aesthetics' design philosophy, it utilized rear-wheel/four-wheel drive architecture, equipped with CTB technology and iTAC intelligent torque control technology. Additionally, it featured front double-wishbone and rear five-link independent suspension, along with the BYD DiSus Intelligent Body Control System. Currently, the Ocean Series boasts several popular models such as the Dolphin, Seal, establishing a robust Ocean Series IP. In the future, the Ocean Series would consolidate SUV models under the intellectual property of Sea Lion* and sedan models under the intellectual property of Seal.
Denza D9 PREMIER (inaugural edition with four seats) Showcased its Intelligent Configurations
Denza, another high-end sub-brand under BYD's diversified brand matrix, presented the D9 PREMIER (inaugural edition with four seats) along with several cutting-edge technologies. The exterior of D9 PREMIER (inaugural edition with four seats) adopted a galaxy dual-tone body, and the interior featured the application of intangible cultural heritage gilding techniques. The cabin was equipped with 22 DEVIALET audio speakers and a premier intelligent customized cockpit, including an 8-inch armrest screen.
In December, high-speed NOA (Navigate on Autopilot) will be rolled out to consumers, followed by the gradual release of urban NOA in Q1 of next year. High-speed NOA-enabled vehicles will be delivered to consumers in December. Additionally, features such as Sentry Mode, Light Map Mode, and Commute Mode will progressively roll out next year.
FANGCHENGBAO and the Stunning BAO 5
BYD's professional personalized sub-brand FANGCHENGBAO also brought its BAO 5 to the exhibition. The BAO 5, which was just launched last week, positioned itself as a "Super Hybrid Hardcore SUV" starting at 289,800 RMB and was equipped with BYD's core technologies such as DMO and DiSus-P. BAO 5 used the ultra-safe blade battery, which adopted a 5-layer protection structure and was shielded by a ring-type double protection system.
BYD had a total of 4 booths at the 21st Guangzhou International Automobile Exhibition, which continued until November 26th. Various of BYD’s hardcore technologies, including the Dual Mode Off-road (DMO) Super Hybrid Platform, BYD DiSus Intelligent Body Control System, and e⁴ Platform also made appearances by some display platforms at this exhibition. BYD demonstrated its pioneer technology and leading advancements, contributing to helping cool the earth by 1℃.
(The product name with the "*" mark in this press release is a translation from the Chinese product name and is currently only applicable for the expressions of models launched in China.)
About BYD
BYD is a multinational high-tech company devoted to leveraging technological innovations for a better life. Founded in 1995 as a rechargeable battery maker, BYD now boasts a diverse business scope covering automobiles, rail transit, new energy, and electronics, with over 30 industrial parks in China, the United States, Canada, Japan, Brazil, Hungary, and India. From energy generation and storage to its applications, BYD is dedicated to providing zero-emission energy solutions that reduce global reliance on fossil fuels. Its new energy vehicle footprint now covers 6 continents, over 70 countries and regions, and more than 400 cities. Listed in both Hong Kong and Shenzhen Stock Exchanges, the company is known to be a Fortune Global 500 enterprise that furnishes innovations in pursuit of a greener world.
For more information, please visit www.bydglobal.com.
About BYD Auto
Founded in 2003, BYD Auto is the automotive subsidiary of BYD, a multinational high-tech company devoted to leveraging technological innovations for a better life. Aiming to accelerate the green transition of the global transportation sector, BYD Auto focuses on developing pure electric and plug-in hybrid vehicles. The company has mastered the core technologies of the entire industrial chain of new energy vehicles, such as batteries, electric motors, and electronic controllers. It has witnessed in recent years significant technological advancements, including the Blade Battery, DM-i Super Hybrid Technology, e Platform 3.0, CTB Technology, e⁴ Platform, BYD DiSus Intelligent Body Control System, and DMO super hybrid system. The company is the world's first carmaker to stop the production of fossil-fueled vehicles on the EV shift and has remained top of new energy passenger vehicle sales in China for 10 years in a row.
For more information, please visit www.byd.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231120172380/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
